Learning From Cancer: Extending Cell Viability by Telomerase Modulation

Modade Sola-Ojo[a]

[a]Landmark University

Department of Chemical Engineering, Landmark University, PMB 1001, Omu-Aran, Kwara State, Nigeria.[a]

Corresponding author: Modade Sola-Ojo, Email: sola-ojo.modade@lmu.edu.ng

Abstract

Normal cells age because their telomeres shorten with every division, eventually reaching a point known as the Hayflick limit. Cancer cells avoid this fate by keeping telomerase active, giving them the ability to divide indefinitely. This commentary asks whether the same principle, if tightly controlled, could be turned toward useful ends. Control of telomerase in normal cells might promote their longevity in bioprocesses where culture stability is paramount, or in regenerative medicine, where tissues need more time to regenerate. The idea is simple, but the path forward requires serious effort to ensure safety and long-term control. In essence, understanding cancer to apply its strategic hallmarks in ways that benefit human health and technology.

Keywords

Cellular Longevity; Cancer Biology; Bioprocessing; Regenerative Medicine; Telomerase;

1. Introduction

The pursuit of cellular longevity has been well explored as central to biomedical and bioprocess engineering. Cells die as part of the natural process in which their division potential is limited by progressive telomere shortening, reaching a point described as the Hayflick limit (Effros & Walford, 1984). This phenomenon is a natural safeguard for uncontrolled proliferation, but it also limits the durability of cells for therapeutic and industrial applications. Cancer cells, however, have particularly mastered strategies to bypass this constraint, mainly through telomerase reactivation (kumar & Sethi, 2023). This results in replicative immortality, one of the canonical hallmarks of cancer (Blagosklonny, 2022).

While typically considered to be a pathological adaptation, telomerase activation in cancer cells may also be viewed as a molecular blueprint for sustained cell viability. From an engineering perspective, we can question whether the mechanisms that sustain cancer cells' survival can be repurposed to extend the functional lifespan of normal cells under strict control. This paper explores telomerase modulation as a route for extending cell viability. In regenerative medicine, cell durability constraints the scalability of stem cell expansion, and in bioprocessing, it can lead to lower yields (Lee et al., 2022). In these cases, controlled telomerase reactivation may offer a path towards enhanced performance, with strong integration of safety suicide switches.

By reframing telomerase as more than an oncogenic driver, we aim to highlight the potential that crosses cancer biology, regenerative medicine, and biotechnology, surrounding how cancers' mastery of telomerase regulation could translate into safe and purposeful applications.

2. Telomerase in Cancer

Cancer cells abnormally bypass replicative limits as opposed to healthy somatic cells. Telomeres are a repetitive nucleotide sequence at chromosome ends that shorten with each cell division. They eventually lead to senescence when shortened to the maximum limit. Malignant cells can bypass this by the reactivation of telomerase or through alternative mechanisms that lengthen telomeres. It has been revealed that this reactivation is caused by promoter mutations in the Telomerase Reverse Transcriptase (TERT) gene and epigenetic remodeling (Liu et al., 2024). These mechanisms are well established in cancer biology. What is more instructive for engineering, however, is the principle they illustrate. These mechanisms demonstrate that the human body already has the machinery to support indefinite proliferation. The challenge then poses whether this can be well controlled to our benefit.

3. Extending Cell Viability

In biotechnology, improved cell viability means a better process. Mammalian cell lines, such as the Chinese Hamster Ovary (CHO) cells and genetically modified human cells, dominate the production of therapeutic proteins and antibodies (Sharker & Rahman, 2021). As more demand for biologics arises, scale-up of these technologies is needed.

Current methods to improve the viability of cell cultures rely on medium optimization, stress response regulation, or clone selection towards more resistant clones (Kasemiire et al., 2021). While these approaches have essentially improved performance, they do not fundamentally alter the lifespan of cells. The persistence of tumor cells to undergo countless divisions suggests that sustained telomere maintenance is plausible. Transient telomere activation could serve as a control lever to extend production cycles. Conceptually, telomerase modulation could be considered as a process variable similar to temperature or nutrient feed rate. Synthetic biology offers routes for such control, including inducible promoters, feedback-regulated gene circuits, or molecular suicide switches to ensure reversibility. The potential advantages are extended batch duration and improved consistency in product quality.

4. Challenges and Ethical Considerations

Telomerase activation is a hallmark of cancer. Attempting to prolong cell lifespan by upregulation of telomerase poses the risk of malignant transformation; carefully controlled strategies, such as tissue-specific activation, are necessary to develop.

Another point of challenge is the delivery system for telomerase activation. In order to extend the life of cells, there has to be a system to activate or enhance telomerase in the targeted cell. Inducers such as genetic and chemical ones are being explored, but fine-tuning is necessary to avoid

affecting any other cells. Even small errors in how these systems are delivered cold have long-term consequences, especially in regenerative medicine, where modified cells remain in the body.

From the ethical point of view, attempts to extend the length of human cell lifespans deliberately fuel more questions about aging. If these technology translate from lab studies to clinical applications, conversations on equitable access and unforeseen social consequences should inevitably follow.

5. Future Outlook

Several pathways of research into telomerase modulation are worth close attention. Gene regulation technologies combined with synthetic biology are capable of designing cell circuits that could activate telomerase under controlled conditions, and offer additional safety layers such as suicide switches. Industrially, extending useful lifespans is a good approach to large-scale bioproduction, where maintaining viable cultures is critical, and regenerative medicine, where tissues with greater replicative resilience are needed. Future studies can integrate molecular tools with systems-level design to determine where such modulation will be effective, safe, and ethically acceptable.

6. Conclusion

Cancer shows us what happens when telomerase is left uncontrolled. We question if we repurpose just enough of that strategy without crossing into danger? Extending cell life could be helpful in very practical ways, from keeping cell cultures viable for longer production to supporting tissues in repair. The task ahead is to learn how to apply this idea with restraint so that the benefit of added time does not come at the cost of safety.

References

Blagosklonny, M. V. (2022). *Aging*, *14*(9), 4176–4187. https://doi.org/10.18632/aging.204082

Effros, R. B., & Walford, R. L. (1984). *9*(1), 49–65. https://doi.org/10.1016/0198-8859(84)90006-5

Kasemiire, A., Avohou, H. T., De Bleye, C., Sacre, P.-Y., Dumont, E., Hubert, P., & Ziemons, E. (2021). *European Journal of Pharmaceutics and Biopharmaceutics*, *166*, 144–154. https://doi.org/10.1016/j.ejpb.2021.06.004

kumar, N., & Sethi, G. (2023). *Cancer Letters*, *578*, 216459. https://doi.org/10.1016/j.canlet.2023.216459

Lee, B., Jung, S., Hashimura, Y., Lee, M., Borys, B. S., Dang, T., Kallos, M. S., Rodrigues, C. A. V., Silva, T. P., & Cabral, J. M. S. (2022). *Bioengineering*, *9*(3), 92. https://doi.org/10.3390/bioengineering9030092

Liu, M., Zhang, Y., Jian, Y., Gu, L., Zhang, D., Zhou, H., Wang, Y., & Xu, Z.-X. (2024). *Cell Death & Disease*, *15*(1), 90. https://doi.org/10.1038/s41419-024-06454-7

Sharker, S. M., & Rahman, A. (2021). *Current Drug Discovery Technologies*, *18*(3), 354–364. https://doi.org/10.2174/1570163817666200312102137